Search
for
Sort by
Research 31–60 of 1000+
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
- BH21 Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis
- P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Alopecia Areata
- S116 Treatment of Concomitant Alopecia Areata and Crohn’s Disease in a Young Child With Tofacitinib: Case Report
- Treatment of severe alopecia areata with baricitinib
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Advances in the mechanism and new therapies of alopecia areata
- Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- Baricitinib for alopecia areata
- Hair loss disorders (alopecias)
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- 73571 The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs